Department of Clinical Education, Canadian College of Naturopathic Medicine, Toronto, ON, Canada.
Department of Clinical Epidemiology and Biostatistics, Health Research Methods, McMaster University, Hamilton, ON, Canada.
HIV Med. 2018 Feb;19(2):143-151. doi: 10.1111/hiv.12563. Epub 2017 Nov 6.
Based on a growing body of evidence implicating low vitamin D status in the development of cardiovascular disease (CVD), we hypothesized that in Canadian HIV-positive adults, low 25-hydroxyvitamin D (25(OH)D) concentration would be associated with increased subclinical vascular disease progression.
We prospectively studied the relationship between baseline 25(OH)D and subsequent progression of carotid intima-media thickness (CIMT) between 2002 and 2011, in the Canadian HIV Vascular Study using stored blood specimens.
Of the 128 participants, 89.1% were men, the mean age (standard deviation [SD]) was 46.5 (8.2) years, 93.8% were white, and 36.7% were current smokers. Mean (SD) annual CIMT follow-up was 5.9 (1.8) years (maximum 8.5 years), providing approximately 750 patient-years of follow-up. Mean (SD) CIMT progression was 0.027 (0.030) mm/year. Mean (SD) 25(OH)D was 95.0 (46.9) nmol/L. Only 13.3% of participants were vitamin D deficient (25(OH)D < 50 nmol/L), whereas 61.7% had a 25(OH)D exceeding the sufficiency threshold (75 nmol/L). Vitamin D quartiles were inversely associated with body mass index (BMI) (P = 0.034), total cholesterol to high-density lipoprotein (HDL) cholesterol ratio (P = 0.001) and parathyroid hormone concentration (P = 0.003), but not efavirenz exposure (P = 0.141). In linear regression analyses, baseline 25(OH)D as a continuous variable was inversely associated with CIMT progression in univariable (P < 0.001) and multivariable (P < 0.001) models.
Baseline 25(OH)D was associated with CIMT progression in this relatively vitamin D replete, predominately white and male, Canadian HIV-positive population. Future research needs to establish causality as this may warrant more targeted screening or supplementation.
基于越来越多的证据表明维生素 D 状态低下与心血管疾病(CVD)的发生有关,我们假设在加拿大 HIV 阳性成年人中,低 25-羟维生素 D(25(OH)D)浓度与亚临床血管疾病进展增加有关。
我们前瞻性研究了 2002 年至 2011 年期间,在加拿大 HIV 血管研究中使用储存血液样本,基线 25(OH)D 与颈动脉内膜中层厚度(CIMT)随后进展之间的关系。
128 名参与者中,89.1%为男性,平均年龄(标准差[SD])为 46.5(8.2)岁,93.8%为白人,36.7%为当前吸烟者。平均(SD)每年 CIMT 随访时间为 5.9(1.8)年(最长 8.5 年),提供了大约 750 名患者年的随访。平均(SD)CIMT 进展为 0.027(0.030)mm/年。平均(SD)25(OH)D 为 95.0(46.9)nmol/L。只有 13.3%的参与者维生素 D 缺乏(25(OH)D < 50 nmol/L),而 61.7%的参与者 25(OH)D 超过了充足阈值(75 nmol/L)。维生素 D 四分位数与体重指数(BMI)呈负相关(P = 0.034),与总胆固醇与高密度脂蛋白(HDL)胆固醇比值(P = 0.001)和甲状旁腺激素浓度(P = 0.003)呈负相关,但与依非韦伦暴露无关(P = 0.141)。在单变量(P < 0.001)和多变量(P < 0.001)模型中,基线 25(OH)D 作为连续变量与 CIMT 进展呈负相关。
在这个相对维生素 D 充足、以白人和男性为主的加拿大 HIV 阳性人群中,基线 25(OH)D 与 CIMT 进展有关。未来的研究需要确定因果关系,因为这可能需要更有针对性的筛查或补充。